Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer

Lung and bladder cancers are difficult to treat because of the development of drug-refractory metastases. Chrysostomou et al. show that the p90 ribosomal protein S6 kinase 4 (RSK4) is involved in the development of chemotherapy resistance and metastatic invasion in both in vitro and in vivo models. Identification of a binding site for floxacin antibiotics on RSK4 led to the finding that…

Read the full article here

Related Articles